T-DM1 Reduces HER2+ Breast Cancer Recurrence.

Findings from the phase III KATHERINE trial show that patients with residual HER2+ breast cancer after neoadjuvant treatment are half as likely to develop invasive disease recurrence if they are treated with T-DM1 instead of trastuzumab, the current standard of care. ©2019 American Association for Cancer Research.